< Back to previous page
Patent
Humanised adamts13 binding antibodies
The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.
Patent Publication Number: EP3642235
Year filing: 2020
Year approval: 2021
Year publication: 2020
Status: Requested
URI: link to Espacenet
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven